Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

ClinicalTrials.gov ID: NCT00542009

Public ClinicalTrials.gov record NCT00542009. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 27, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Phase 2A, Randomized, Subject And Investigator Blinded, Placebo-Controlled Trial To Evaluate The Safety, Tolerability And Efficacy Of CE-326,597 On Glucose Control And Body Weight In Overweight Adult Subjects With Type 2 Diabetes Mellitus

Study identification

NCT ID
NCT00542009
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
252 participants

Conditions and interventions

Interventions

  • CE-326,597 100 mg QD Drug
  • CE-326,597 50 mg QD Drug
  • CE-326,597 25 mg QD Drug
  • Placebo Drug
  • CE-326,597 5mg QD Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2007
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008
Last update posted
Nov 6, 2012

2007 – 2008

United States locations

U.S. sites
30
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85023
Pfizer Investigational Site Fresno California 93720
Pfizer Investigational Site National City California 91950
Pfizer Investigational Site San Diego California 92128
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Ocala Florida 34471
Pfizer Investigational Site West Palm Beach Florida 33401
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Conyers Georgia 30094
Pfizer Investigational Site Honolulu Hawaii 96814
Pfizer Investigational Site Idaho Falls Idaho 83404
Pfizer Investigational Site Chicago Illinois 60607
Pfizer Investigational Site Chicago Illinois 60654
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Bethesda Maryland 20817
Pfizer Investigational Site Chaska Minnesota 55318
Pfizer Investigational Site Minneapolis Minnesota 55455
Pfizer Investigational Site Jackson Mississippi 39202
Pfizer Investigational Site Henderson Nevada 89052
Pfizer Investigational Site Las Vegas Nevada 89101
Pfizer Investigational Site Las Vegas Nevada 89117
Pfizer Investigational Site Fargo North Dakota 58103
Pfizer Investigational Site Cincinnati Ohio 45249
Pfizer Investigational Site Lansdale Pennsylvania 19446
Pfizer Investigational Site Rapid City South Dakota 57702
Pfizer Investigational Site Beaumont Texas 77701
Pfizer Investigational Site Beaumont Texas 77706
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site Richmond Virginia 23294

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00542009, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2012 · Synced Jun 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00542009 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →